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Background: Depression is the most widely acknowledged psychological problem among end-stage renal disease
(ESRD) patients. Depression may be associated with VD deficiency. The aims of this study are to (a) elucidate the
prospective association between HsCRP, VD contents and depressive symptoms in the dialyzed population, and
(b) find the effect of calcitriol supplementation on depression in dialyzed patients.
Methods: In this prospective study, 484 dialysis patients (382 hemodialysis [HD] cases and 102 peritoneal dialysis
[PD] cases; aged 18–60 years) from two hospitals in southeast China were included. The depression in these
patients was evaluated using the Chinese version of Beck’s Depression Inventory (BDI). All subjects answered the
BDI-I questionnaire for assessment of depression levels in summer. A cut-off value of 16 was set to include dialysis
patients with depression. All patients were divided into two groups depending on the absence (Group1) or presence
(Group 2) of depression. The two groups took 0.5 μg/day 1,25-Dihydroxyvitamin D orally for one year. BDI Scores were
recalculated for all patients. Sociodemographic, clinical data, and serum VD contents were also collected.
Results: A total of 484 participants (247 men [51.0%] and 237 women [49.0%]) were surveyed. Depressive symptoms
were found in 213 (44.0%) patients. The baseline serum VD level (VD2 + VD3) was 17.6 ± 7.7 nmol/L. Patients with
depressive symptoms have significantly higher serum HsCRP level and significantly lower serum VD level compared
with the control group. After one-year follow-up, the supplementation of 0.5 μg/day calcitriol slightly improved the
microinflammatory state such as lowering mean serum HsCRP level and improving serum VD level, but not in
significantly enhancing the depressive symptoms.
Conclusions: Calcitriol supplementation did not significantly enhance the depressive symptoms in our dialyzed
population although patients with low levels of serum VD were more depressed. Therefore, more prospective
randomized controlled trials are necessary to reveal the exact cause-and-effect relationship between VD status and
depressive symptoms or VD status related to some specific subtypes in dialyzed patients.
Keywords: Depression, Vitamin D, End-stage renal disease, Dialysis, Efficacy, Prospective studyBackground
Depression ranks fourth on the World Health Organization
(WHO) global disease burden list. Depression is the most
widely acknowledged psychological problem among end-
stage renal disease (ESRD) patients [1,2]. About 28% of
chronic kidney disease patients facing impending dialysis
undergo major depression, and even a larger proportion of
dialyzed patients suffer from depression [3]. Inflammation* Correspondence: jishengz2013@163.com
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unless otherwise stated.in the body is a common manifestation to many diseases,
including high blood pressure, coronary artery disease,
diabetes as well as chronic kidney disease [4,5]. Recently,
many authors have tried to reveal the connection between
depression and inflammatory status in ESRD patients
[6,7]. Depression is also linked to an inflammation marker
in blood called C-reactive protein (CRP). Proinflammatory
cytokines were proven very important in the pathogenesis
of depression in the general population and the levels of
the same cytokines elevated in ESRD patients [8]. How-
ever, repeated episodes of depression contribute to inflam-
mation in the body, which highlights a potentiallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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to a series of serious medical problems [9]. The causality
between depression and inflammation is still unclear.
Vitamin D (VD) is an essential nutrient for bone
health, and has other physiological functions. There are
plausible reasons for investigating the curative effects of
VD for depressive disorders. Depression may be associ-
ated with VD deficiency [10-12]. Hypovitaminosis D and
secondary hyperparathyroidism commonly occur in the
dialyzed population for several reasons [13,14]. There-
fore, Calcitriol supplementation is popular among dialyzed
patients. However, spontaneous 25(OH)D levels > 20
ng/mL seem sufficient to control serum intact parathy-
roid hormone (iPTH) in chronic kidney disease (CKD)
patients [15]. These findings reinforce the guidelines to
supplement VD only if less than 30 ng/mL. In China,
Calcitriol is used as a form of VD to treat hypovitami-
nosis D and secondary hyperparathyroidism in patients
whose kidneys or parathyroid glands are not working
normally.
However, it is unknown whether serum VD content is
associated with depression in the dialyzed population
and whether calcitriol supplementation is efficient for
treatment of depression. The intentions of this study
were to (a) investigate the prospective association be-
tween HsCRP, VD contents and depressive symptoms in
the dialyzed population, and (b) find the efficacy of calci-
triol supplementation on depression in dialyzed patients.Methods
Participant selection
In this prospective study, we included a total of 484 pa-
tients receiving dialysis (382 hemodialysis [HD] cases
and 102 peritoneal dialysis [PD] cases) from two hospi-
tals in China. All patients aged 18–60 who had received
HD or PD for more than 3 months were screened for
participation. Signed informed consent was required for
enrollment, and after that, patients received oral and
written information about the study. Ethical permission
for the study was obtained from the Scientific Ethical
Committee in Beilun Branch of the First Affiliated Hos-
pital of Zhejiang University (Approval No. 2012033).Exclusion criteria
Exclusion criteria: 1, cognitive deficits such as consider-
able memory loss, confusion/dementia, and intellectual
disability; illiteracy and/or incapability of answering the
questionnaire (difficulty in understanding the questions,
visual or hearing impairment); 2, Evidence shows that
the incidence of depression may increase in older pa-
tients compared with normal adults [16]. Thus, the pa-
tients more than 60 years old were excluded from this
study; 3, Patients used antidepressant medications inrecent two years; 4, Patients had severe depressive symp-
toms before dialysis.
Depressive symptoms and division
Depression is a condition characterized by depressed
mood or loss of interest or pleasure in nearly all activ-
ities almost every day for at least 2 weeks. The presence
of depressive symptoms was determined using a Chinese
version of Beck’s Depression Inventory (BDI) in summer,
and the Chinese version was previously validated as the
English version [17-20]. The BDI consists of 21 self-
reported items and each item is rated on the scale of 0–
3, producing a possible score range from 0 to 63. A
higher score correlates with more severe depression
[21]. BDI score >16 is characteristic for presence of
moderate to severe depressive symptoms. A cut-off value
of 16 was set to include the dialyzed patients with de-
pression [22,23]. BDI score ≥ 30 was defined as severe
depression symptoms [24,25]. Structured interview was
conducted to determine diagnoses and severity of de-
pression for each patient by two experienced psychiatrist
independently.
All patients were divided into two groups depending
on the absence or presence of depression. In China, dia-
lysis patients usually took 1,25- Dihydroxyvitamin D
(Calcitriol, Roche, Shanghai, China) orally 0.25 - 0.5 μg/
day or 1.25 μg - 2.5 μg twice a week. Therefore, the two
groups took 0.5 μg/day calcitriol orally for one year, and
BDI scores were recalculated.
Demographic and clinical data at baseline
Demographic data including employment status and
education status were collected by questioning the pa-
tients. Information concerning age, sex, primary kidney
disease, dialysis modality, comorbidities, health insur-
ance, and mean time on dialysis (months) was gathered
from medical records. Comorbidity was scored on the
number of comorbid conditions using the comorbidity
index according to a previous study [26].
Blood was collected according to a standard protocol.
Laboratory data including levels of intact parathyroid hor-
mone (iPTH), serum albumin, high sensitive C-reactive
protein (hsCRP) and serum calcium were gathered from
medical records. Serum VD (VD2+ VD3) levels were ana-
lyzed using liquid chromatography–mass spectrometry
(LC-MS, or the gold standard high-performance liquid
chromatography [HPLC]-MS [27,28]) at the Kingmed
Diagnostics Laboratory, Guangzhou, China.
25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in
serum were detected with HPLC-MS according to a pre-
vious study [29]. Human serum (150 μL) was diluted in
450 μL of 2-propanol containing butylated hydroxyto-
louene as an antioxidant. After thorough mixing (15 min)
and centrifugation (10 min, 4000 g at 10°C), an aliquot of
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system. HPLC was performed with an HP 1100 liquid
chromatograph interfaced by atmospheric pressure chem-
ical ionisation to an HP mass spectrometric detector oper-
ated in the single ion monitoring mode. VD analogues
were separated on a 4.6 mm× 50 mm reversed phase
column with 1.8 μM particles. The column temperature
was 80°C. A two-point calibration curve was plotted
from analysis of an albumin solution with known VD
concentration.
Statistical analysis
We calculated and proved that a sample of 484 patients
provided adequate power (α = 0.05 in two-sided t-test)
for the proposed tests in this two-group study. Changes
in HsCRP, VD contents and BDI scores from the base-
line to the one-year follow-up were presented in a figure
with 2 panels of the mean and error bars of each vari-
able. The results were expressed as mean ± standard de-
viation (SD) and P < 0.05 was considered significant. The
prevalence of depression was evaluated using frequency
analysis and 95% confidence intervals (CIs). Differences
in means were tested using an independent t-test, or
Mann–Whitney test. Quartiles were compared with one-
way analysis of variance (ANOVA), Kruskal–Wallis test,
or χ2 test as appropriate. The effects of the VitD treat-
ment were examined using 2x2 ANOVA.
The independent risk factors associated with BDI
scores in dialysis patients were defined using multiple
linear regression analysis. Depression can be affected by
many factors including sex, marital stage, employment
status, health insurance, living, comorbidity index, dialy-
sis modality, hemoglobin, serum albumin, sensitive C-
reactive protein, and VD. Therefore, all analyses were
adjusted for those variables. All statistical analyses were
evaluated using SPSS 17.00 (IBM Corporation, Armonk,
NY, USA).
Results
Baseline characteristics and assessment of depressive
symptoms in dialyzed patients
The 484 respondents were aged 52.7 ± 15.9 years on
average. Their general characteristics are presented in
Table 1. There were some differences in age, sex, comor-
bidity index, mean hemoglobin, mean sensitive C-reactive
protein, and mean serum VD.
The baseline serum VD (VD2+ VD3) level of the dia-
lyzed population was 11.9 ± 6.8 (3.6 to 32.5) nmol/L.
Overall BDI score for the studied population was 17.3 ±
7.2 points. Moderate to severe depressive symptoms
(BDI score > 16) were found in 213 (44.0%, 95% CI:
−0.137-0.027) patients. The depression group has signifi-
cantly higher serum HsCRP level (9.7 ± 3.3 vs. 7.8 ±
2.6 mg/l; p = 0.014) and significantly lower serum VDlevel (15.4 ± 5.1 vs. 19.3 ± 9.7 mg/l; p = 0.032) compared
with the non-depression group.
Risk factors for depression in the dialyzed patients
The independent risk factors associated with BDI score
in dialysis patients were defined using multiple linear re-
gression analysis. The independent variables such as age,
sex, marital stage, employment status, health insurance,
living, comorbidity index, and dialysis modality were
inserted in the analysis with the BDI scores as criterion.
Only sex and comorbidity index were independently as-
sociated with BDI scores, indicating that (1) The females
were more likely to have higher BDI scores compared
with males; (2) the dialysis patients with more comorbid
conditions were more likely to have higher BDI scores
compared with those with less comorbid conditions; (3)
Patients with higher BDI scores have significantly higher
serum HsCRP level and significantly lower serum VD
level, not vice-versa.
Efficacy of calcitriol supplementation on treatment of
depression in dialyzed patients
Data on serum HsCRP level, VD (VD2+ VD3) levels, and
BDI scores after one year follow-up are listed in Figure 1.
Calcitriol supplementation slightly improved the microin-
flammatory state such as lowering mean serum HsCRP
level (8.2 ± 1.7 vs. 9.7 ± 3.3, P = 0.027/6.5 ± 2.1 vs. 7.8 ± 2.6,
P = 0.042), but associations did not substantially change
when depression was included in the model in dialysis
population.
Discussion
This prospective study provided a comprehensive and
detailed description of the incidence of depression and
the effect of calcitriol supplementation on treatment of
depression in dialyzed patients. The overall incidence of
depression was (44%, 95% CI: −0.137-0.027) in the dia-
lyzed patients, which was consistent with previous re-
ports [30-32]. The high occurrence of depression may be
partly due to anemia and poor nutritional status in the
dialyzed population [33]. Moreover, employment status,
health insurance mode, marital status, and constipation
status can all affect the incidence of depression. In our
study, anemia (hemoglobin level) and nutritional status
(albumin) were also evaluated, and there was differ-
ence in mean hemoglobin level, but not in mean albu-
min level. Thus, we thought depression for dialysis
patients was multifactorial apart from poor nutritional
status.
The depressive patients have higher serum HsCRP
level than the non- depressive patients, and thus CRP
may be as a new risk factor of depression in the dialyzed
population. Also HsCRP level can be used to predict the
outcome in HD patients. After one-year follow up,
Table 1 Socialdemographic and clinical datas between depression and non-depression groups
Characteristics Group1 (BDI score 0 ~ 16)
(n = 271)
Group2 (BDI score > 16)
(n = 213)
P value
Age (Yr) 49.7 ± 19.0 56.5 ± 12.0 0.03
Female sex. No. (%) 99 (36.5) 138 (64.8) <0.001
Dialysis modality (haemodialysis, %) 209 (72.1) 173 (82.1) 0.32
Marital status. No. (married, %) 221 (81.5) 165 (77.5) 0.32
Employment status (Employed) 180 (66.4) 134 (62.9) 0.48
Primary kidney disease. No. (%) 0.41
Nephritis 149 (55.0) 126 (59.1)
Hyptertensive nephrosclerosis 14 (5.2) 10 (4.7)
Diabetic nephrology 18 (6.6) 44 (20.7)
Polycystic kidney disease 17 (6.3) 13 (6.1)
Other 73 (26.9) 19 (9.4)
Health insurance modes. No. (%) 0.61
The medical insurance 210 (77.5) 160 (75.1)
The new rural insurance 61 (22.5) 53 (24.9)
Education 0.09
UP to high school 55 (20.3) 58 (27.2)
Beyond high school 216 (79.7) 155 (72.8)
living along 7 (2.6) 13 (6.1) 0.08
Mean hemoglobin (g/l) (mean ± SD) 12.4 ± 5.7 10.8 ± 1.7 0.04
Mean serum calcium (g/l) (mean ± SD) 2.4 ± 0.6 2.2 ± 0.9 0.57
Mean serum albumin (g/l) (mean ± SD) 35.3 ± 6.8 34.3 ± 2.7 0.63
Serum vitamin D (nmol/l) (mean ± SD) 19.3 ± 9.7 15.4 ± 5.1 0.032
Plasm iPTH (pmol/l) (mean ± SD) 213.6 ± 89.4 197.4 ± 103.5 0.08
High sensitive C-reactive protein (mg/l) (mean ± SD) 7.8 ± 2.6 9.7 ± 3.3 0.014
Mean time on dialysis (months) (mean ± SD) 56.5 ± 12.2 47.6 ± 16.2 0.42
Comorbidity index (mean ± SD) 5.5 ± 0.3 7.8 ± 3.1 0.007
Differences in proportions were tested using Pearson chi-square test; differences in means were tested using an Independent t-test, or Mann–Whitney.
Abbreviation: n number, iPTH intact parathyroid hormone.
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mean serum HsCRP, which was not accompanied by the
improvement of depressive symptoms. The causality be-
tween depression and inflammation is not well clear. De-
pression was linked to worse nutritional status in ESRD
patients, [34] indicating that repeated episodes of de-
pression contribute to inflammation, rather than inflam-
mation contribute to depression in the body [9].
We did find an association between depressive symp-
toms and serum VD (VD2+ VD3) levels in the dialyzed
population. The patients with higher serum VD levels at
baseline tended to have fewer depressive symptoms. Re-
cently, the possible link between depression and VD sta-
tus has been investigated in several small studies, but
the findings are inconsistent because of differences in
races, study populations, geographic locations and meth-
odologies [35-39]. In particular, the depressive state may
be a cause rather than a consequence of VD deficiency,because if depression caused VD deficiency owing to
lack of sunlight exposure, then the association between
VD levels and depressive symptoms would be stronger
in the summer months when VD levels are most
strongly influenced, which was not evident in this sam-
ple. Serum VD level is related to physical activity (time
spent outdoors), body mass index (BMI), chronic dis-
eases, social status and nutritional status. Luigi Ferrucci
et al. explored whether low VD levels and depression in
older people were related [40]. They did not find that
low vitamin D levels can cause depression, and thus they
thought other characteristics might predispose people
with low nutrient levels to depression [40]. Also the
most important one probably is that people with low VD
are likely to have all these pathological problems associ-
ated with low VD and these problems can cause depres-
sion. Therefore, prospective research is required to
clarify the direction of cause and effect [40].
Figure 1 Mean serum HsCRP, serum vitamin D level and BDI scores between groups after one year follow up. HsCRP, hypersensitive C
reactive protein. Mean serum HsCRP in mg/l and serum vitamin D level in nmol/l. BDI, Beck Depression Inventory, with the score ranges from 1
to 63, with higher score indicating more severe depressive symptoms. Control, before treatment; treated, after treatment.
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VD is considered as a neurosteroid across the blood–
brain barrier. The VD receptors widespread in the brain
include the hippocampus, which is associated with the
development of depression. In our intervention, we did
not find a significant effect of calcitriol supplementation
on enhancing the depressive symptoms in the dialyzed
population, since the effects are also conflicting [41-43].
There are some reasons for this result. First, calcitriol
supplementation did not significantly enhance the de-
pressive symptoms in the dialyzed population since we
did not find the correct cause-and-effect relationship be-
tween VD and depression. Second, some causes lead to
the opposite result: (1) The tested dose of VD (0.5 μg/day) might be insufficient to affect the occurrence of de-
pression, and the VD intake from food sources was ig-
nored. (2) One year was a rather short time frame for
investigation of depression, since depression may de-
velop slowly and last for several years. (3) BDI scores re-
flect the self-report of depressive symptoms, but it was
controversial that a cut-off value of 16 was set to include
the patients with depression (Some study chosen BDI
score ≥ 20 as moderate to severe depression) [44]. It
stressed that calcitriol supplementation can improve car-
diovascular symptoms, [45,46] and reduce vascular de-
pression, but many reasons may induce the occurrence
of depression in dialyzed population. Additionally, we
use the dialyzed patients as objects for the first time.
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Specifically, although we assessed a broad range of de-
pressive disorders, it is difficult to ascertain the specific
causes of depression within the sample. Second, We did
not subdivide the patients with depression: one group
treated with the active compound and one treated with
placebo. It was not a randomized double-blind trial
study. Thirdly, the dose of 0.5 μg calcitriol for dialyzed
patients is far enough for curing depression. Moreover,
the sample in our study is far smaller than enough.
Conclusions
Even though people with low levels of serum VD were
more depressed, Calcitriol supplementation did not sig-
nificantly enhance the depressive symptoms in our dialy-
sis population. More prospective randomized controlled
trials are necessary to find the exact cause-and-effect re-
lationship between VD status and depressive symptoms
or VD status related to some specific subtypes in dia-
lyzed patients.
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